Search - tctmd.com

Displaying 61 - 80 of 228

Sort: Relevancy | Date

Presentation TCT 2017

Resolute and Onyx Zotarolimus-Eluting Stents: Device Iterations and Randomized/Registry Outcomes Data in Perspective

Presenter: Stephen G. Ellis, David E. Kandzari, Matthew J. Price

October 30, 2017

Presentation TCT 2017

Are There Meaningful Differences Between Current Durable Polymer-Based vs Bioabsorbable Polymer-Based vs Polymer-Free Metallic DES? Pathologic Insights

Presenter: Giulio G. Stefanini, Stephan Windecker, Renu Virmani

October 30, 2017

Presentation TCT 2017

Promus Element Everolimus-Eluting Stents: Device Iterations and Randomized/Registry Outcomes Data in Perspective

Presenter: Stephen G. Ellis, David E. Kandzari, Sigmund Silber

October 30, 2017

Presentation TCT 2017

XIENCE Everolimus-Eluting Stents: Device Iterations, Randomized/Registry Outcomes Data in Perspective and the Move to Shorter DAPT

Presenter: Stephen G. Ellis, David E. Kandzari, Tullio Palmerini

October 30, 2017

Presentation TCT 2017

HARMONEE: A Randomized Trial of a Bioabsorbable Polymer-Based DES With a Luminal CD34+ Antibody Coating vs a Durable Polymer-Based DES in Patients With Coronary Artery Disease

Presenter: Fernando Alfonso, Mitchell W. Krucoff

October 30, 2017

Presentation ESC 2017

BIOFLOW V Comparison of Ultrathin Sirolimus-Eluting Bioresorbable Polymer with Thin Everolimus-Eluting Durable Polymer Stents

Presenter: David E Kandzari

September 13, 2017

News Industry News

Micro Interventional Devices, Inc.™ Completes First Clinical Tricuspid Bicuspidization Procedure Utilizing MIA™ Technology

September 07, 2017

News Industry News

Medtronic Announces Randomized Global Resolute Onyx(TM) DES One-Month Dual Antiplatelet Therapy Study to Address Critical Unanswered Question in Interventional Cardiology

August 15, 2017

News Conference News EuroPCR 2017

BIO-RESORT: Impaired Glucose Metabolism Linked With Worse Clinical Outcomes After PCI

Michael O'Riordan

May 18, 2017

News Conference News EuroPCR 2017

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Michael O'Riordan

May 16, 2017

News Industry News

Medtronic Launches Resolute Onyx(TM) Drug-Eluting Stent in United States Following FDA Approval Becoming First DES Available in 4.5 mm and 5 mm Sizes

May 02, 2017

News Opinion Editor's Corner

TCTMD’s Top 10 Most Popular Stories for November 2016

Shelley Wood

November 30, 2016

News Conference News TCT 2016

No Scares From SCAAR: Stent Thrombosis Rates in Newest DES Are Similar—and Low

Shelley Wood

November 07, 2016

News Industry News TCT 2016

Imaging Study Shows Rate of Strut Coverage and Low Rates of Neouatherosclerosis with Thin Strut Bioresorbable Polymer-Based and Durable Polymer-Based Drug-Eluting Stents

November 02, 2016

News Industry News TCT 2016

Hybrid Sirolimus-Eluting Stents with Biodegradable Polymer Did Not Improve Angiographic Outcomes Compared to Everolimus-Eluting Stents with Durable Polymer in Treatment of Chronic Total Occlusions

November 02, 2016

News Conference News TCT 2016

TRANSFORM-OCT: Similar Early and Late Healing With Bioresorbable- and Durable-Polymer DES

Michael O'Riordan

November 02, 2016

Presentation TCT 2016

TRANSFORM-OCT: A Prospective, Randomized Trial Using OCT Imaging to Evaluate Strut Coverage at Three Months and Neoatherosclerosis at Eighteen Months in Bioresorbable Polymer-Based and Durable Polymer-Based Drug-Eluting Stents

Presenter: Gary S. Mintz, Robert-Jan van Geuns, Giulio Guagliumi

November 02, 2016

Presentation TCT 2016

PRISON IV: A Prospective, Randomized Trial of a Bioresorbable Polymer-Based Sirolimus-Eluting Stent and a Durable Polymer-Based Everolimus-Eluting Stent in Patients With Coronary Artery Chronic Total Occlusions

Presenter: Gary S. Mintz, Robert-Jan van Geuns, Koen Teeuwen

November 02, 2016

Presentation TCT 2016

TCT 70: Final 5 Year Results from the COMPARE II Trial: Comparison Between the Durable Polymer Coated Everolimus-Eluting Xience/Promus Stent and the Biodegradable Polymer Coated Biolimus-Eluting Nobori Stent in All-Comer Population

Presenter: Giuseppe De Luca, Christoph A. Kaiser, Pieter C. Smits

October 31, 2016

News Conference News TCT 2016

‘Encouraging’ Preliminary Results Seen With Novel, Polymer-Free, Drug-Filled Stent

Todd Neale

October 31, 2016

Advertisement

Resolute and Onyx Zotarolimus-Eluting Stents: Device Iterations and Randomized/Registry Outcomes Data in Perspective

Are There Meaningful Differences Between Current Durable Polymer-Based vs Bioabsorbable Polymer-Based vs Polymer-Free Metallic DES? Pathologic Insights

Promus Element Everolimus-Eluting Stents: Device Iterations and Randomized/Registry Outcomes Data in Perspective

XIENCE Everolimus-Eluting Stents: Device Iterations, Randomized/Registry Outcomes Data in Perspective and the Move to Shorter DAPT

HARMONEE: A Randomized Trial of a Bioabsorbable Polymer-Based DES With a Luminal CD34+ Antibody Coating vs a Durable Polymer-Based DES in Patients With Coronary Artery Disease

BIOFLOW V Comparison of Ultrathin Sirolimus-Eluting Bioresorbable Polymer with Thin Everolimus-Eluting Durable Polymer Stents

Micro Interventional Devices, Inc.™ Completes First Clinical Tricuspid Bicuspidization Procedure Utilizing MIA™ Technology

Medtronic Announces Randomized Global Resolute Onyx(TM) DES One-Month Dual Antiplatelet Therapy Study to Address Critical Unanswered Question in Interventional Cardiology

BIO-RESORT: Impaired Glucose Metabolism Linked With Worse Clinical Outcomes After PCI

DESSOLVE III: MiStent Holds Up Well Against Xience at 12 Months, Hints at Potential Longer-Term Benefit

Medtronic Launches Resolute Onyx(TM) Drug-Eluting Stent in United States Following FDA Approval Becoming First DES Available in 4.5 mm and 5 mm Sizes

TCTMD’s Top 10 Most Popular Stories for November 2016

No Scares From SCAAR: Stent Thrombosis Rates in Newest DES Are Similar—and Low

Imaging Study Shows Rate of Strut Coverage and Low Rates of Neouatherosclerosis with Thin Strut Bioresorbable Polymer-Based and Durable Polymer-Based Drug-Eluting Stents

Hybrid Sirolimus-Eluting Stents with Biodegradable Polymer Did Not Improve Angiographic Outcomes Compared to Everolimus-Eluting Stents with Durable Polymer in Treatment of Chronic Total Occlusions

TRANSFORM-OCT: Similar Early and Late Healing With Bioresorbable- and Durable-Polymer DES

TRANSFORM-OCT: A Prospective, Randomized Trial Using OCT Imaging to Evaluate Strut Coverage at Three Months and Neoatherosclerosis at Eighteen Months in Bioresorbable Polymer-Based and Durable Polymer-Based Drug-Eluting Stents

PRISON IV: A Prospective, Randomized Trial of a Bioresorbable Polymer-Based Sirolimus-Eluting Stent and a Durable Polymer-Based Everolimus-Eluting Stent in Patients With Coronary Artery Chronic Total Occlusions

TCT 70: Final 5 Year Results from the COMPARE II Trial: Comparison Between the Durable Polymer Coated Everolimus-Eluting Xience/Promus Stent and the Biodegradable Polymer Coated Biolimus-Eluting Nobori Stent in All-Comer Population

‘Encouraging’ Preliminary Results Seen With Novel, Polymer-Free, Drug-Filled Stent

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content